Trial Profile

LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Oct 2023 of secondary analysis assessing the efficacy and safety of relugolix combination therapy in the subgroup population of Black/African American women with uterine fibroids, published in the American Journal of Obstetrics and Gynecology
09 Feb 2023 This trial has been discontinued in Poland.
03 Nov 2022 Results of pooled analysis (NCT03049735; NCT03103087; NCT03412890) assessing the long-term efficacy and safety of relugolix combination therapy treatment for up to 52 weeks published in the Obstetrics and Gynecology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com